106 related articles for article (PubMed ID: 19407654)
1. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications.
Chivukula M; Domfeh A; Carter G; Tseng G; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):495-9. PubMed ID: 19407654
[TBL] [Abstract][Full Text] [Related]
2. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma in situ.
Hoshikawa S; Sano T; Hirato J; Oyama T; Fukuda T
Cytopathology; 2016 Apr; 27(2):108-14. PubMed ID: 25810244
[TBL] [Abstract][Full Text] [Related]
4. Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance.
Wasserman JK; Parra-Herran C
Am J Clin Pathol; 2015 Sep; 144(3):503-10. PubMed ID: 26276781
[TBL] [Abstract][Full Text] [Related]
5. Uniqueness of ductal carcinoma in situ of the breast concurrent with papilloma: implications from a detailed topographical and histopathological study of 50 cases treated by mastectomy and wide local excision.
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Shiraiwa M; Morita T; Sato Y; Hayashi T; Kato A; Iwakoshi A; Sato T
Histopathology; 2013 Sep; 63(3):407-17. PubMed ID: 23829486
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
7. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
8. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted imaging (b value = 1500 s/mm(2)) is useful to decrease false-positive breast cancer cases due to fibrocystic changes.
Ochi M; Kuroiwa T; Sunami S; Murakami J; Miyahara S; Nagaie T; Oya M; Yabuuchi H; Hatakenaka M
Breast Cancer; 2013 Apr; 20(2):137-44. PubMed ID: 22161277
[TBL] [Abstract][Full Text] [Related]
10. Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.
Aguiar FN; Cirqueira CS; Bacchi CE; Carvalho FM
Breast Dis; 2015; 35(4):249-52. PubMed ID: 26397772
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma.
Tajima S; Maeda I; Kanemaki Y; Nakajima Y; Tatsunami S; Fukuda M; Takagi M
Pathol Int; 2010 Jun; 60(6):459-65. PubMed ID: 20518901
[TBL] [Abstract][Full Text] [Related]
12. Breast ductal carcinoma in situ presenting as recurrent non-puerperal mastitis: case report and literature review.
Liong YV; Hong GS; Teo JG; Lim GH
World J Surg Oncol; 2013 Aug; 11(1):179. PubMed ID: 23924035
[TBL] [Abstract][Full Text] [Related]
13. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?
Ribeiro-Silva A; Zamzelli Ramalho LN; Garcia SB; Zucoloto S
Pathol Oncol Res; 2003; 9(1):20-3. PubMed ID: 12704442
[TBL] [Abstract][Full Text] [Related]
14. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
17. Changes in breast cancer reports after pathology second opinion.
Marco V; Muntal T; García-Hernandez F; Cortes J; Gonzalez B; Rubio IT
Breast J; 2014; 20(3):295-301. PubMed ID: 24689830
[TBL] [Abstract][Full Text] [Related]
18. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns.
Boecker W; Buerger H; Schmitz K; Ellis IA; van Diest PJ; Sinn HP; Geradts J; Diallo R; Poremba C; Herbst H
J Pathol; 2001 Nov; 195(4):415-21. PubMed ID: 11745672
[TBL] [Abstract][Full Text] [Related]
19. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
20. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
El Sharkawy SL; Farrag AR
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
